Understanding CINV

**WHAT IS CINV?**

CINV stands for chemotherapy-induced nausea and vomiting - common, yet potentially preventable, side effects of chemotherapy. Chemotherapy is a type of cancer treatment that uses drugs to destroy cancer cells.

**APPROXIMATELY 70-80% OF PATIENTS** who do not receive appropriate preventative treatment will experience CINV.

**ACUTE VS. DELAYED**

- **ACUTE CINV OCCURS WITHIN 24 HOURS**
- **DELAYED CINV OCCURS MORE THAN 24 HOURS**

Delayed nausea is often more common and severe than acute nausea.

**IN ONE STUDY, PATIENTS RATED**

#1 NAUSEA, #3 VOMITING as the most distressing symptoms of chemotherapy-related adverse effects.

**CINV MAY BE PREVENTED**

A team approach that includes experts with knowledge about treatments may help patients better prevent their CINV.

There are many treatments aimed at preventing CINV. Medical guidelines recommend treatment options to prevent CINV for the entire time a patient is at risk for nausea and vomiting.

**WHY CINV PREVENTION MATTERS**

Both acute and delayed CINV can have a serious impact on patients.

In one study the number of lost work days per month for patients receiving chemotherapy:

- **$3.61** FOR PATIENTS WITH CONTROLLED CINV
- **$6.23** FOR PATIENTS WITH UNCONTROLLED CINV

Approximately $1,300 more per month of direct medical costs due to CINV-related events such as unscheduled office visits, treatment for dehydration, emergency room admissions and lost work days.

**TIME TO TALK CINV**

Patients should discuss guideline-based therapy with their full healthcare teams, including their oncologists, pharmacists, and nurses, in order to prevent CINV throughout their chemotherapy treatment.

For more information visit HOPArx.org/talkCINV

©2017 Eisai Inc and Helsinn Therapeutics (U.S.), Inc. All rights reserved. Time to Talk CINV™ is a collaboration between the Hematology/Oncology Pharmacy Association, Eisai Inc., and Helsinn Therapeutics (U.S.), Inc. The Time to Talk CINV campaign is funded by Eisai Inc and Helsinn Therapeutics (U.S.), Inc. US0300.